Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to pyrrolobenzodiazepines (PBDs), and is particularly concerned with the use of these compounds as prodrugs for antibody-directed enzyme-prodrug therapy (ADEPT), gene-directed enzyme-prodrug therapy (GDEPT) , photodynamic therapy (PDT) and naturally present enzyme-prodrug therapy (NPEPT) .
• ADPT antibody-directed enzyme-prodrug therapy
• GDEPT gene-directed enzyme-prodrug therapy
• PDT photodynamic therapy
• NPEPT naturally present enzyme-prodrug therapy
• PBDs Pyrrolobenzodiazepines
• PuGPu Purine-Guanine-Purine
• Family members include abbeymycin (Hochlowski et al., 1987 J. Antibiotics, 40, 145-148), chicamycin (Konishi et al., 1984 J. Antibiotics, 37, 200-206), DC-81 (Japanese Patent 58-180 487; Thurston et al., 1990, Chem. Brit., 26, 767-772; Bose et ai . , 1992 Tetrahedron, 48, 751-758), mazethramycin (Kuminoto et al., 1980 J. Antibiotics, 33, 665-667), neothramycins A and B (Takeuchi et al., 1976 J.
• PBDs are of the general structure: O 00/12507
• prodrugs represents a very valuable clinical concept in cancer therapy.
• a prodrug may be converted into an antitumour agent under the influence of an enzyme that is linked to a monoclonal antibody so that it can bind to a tumour associated antigen.
• an enzyme that is linked to a monoclonal antibody so that it can bind to a tumour associated antigen.
• the combination of such a prodrug with such an enzyme monoclonal antibody conjugate represents a very powerful therapeutic strategy.
• This approach to cancer therapy often referred to as "antibody directed enzyme/prodrug therapy" (ADEPT) is disclosed in WO88/07378.
• ADPT antibody directed enzyme/prodrug therapy
• VDEPT virus-directed enzyme prodrug therapy
• Tumour cells are targeted with a viral vector carrying a gene encoding an enzyme capable of activating a prodrug.
• the gene may be transcriptionally regulated by tissue specific promoter or enhancer sequences.
• the viral vector enters tumour cells and expresses the enzyme, thereby converting the prodrug into the active drug within the tumour cells (Huber et al . , Proc. Na tl . Acad. Sci . USA (1991) 88. ⁇ 8039).
• non-viral methods for the delivery of genes have been used.
• GDEPT gene-directed enzyme prodrug therapy
• Photodynamic therapy provides another method which uses prodrugs to deliver desired drugs to specific sites in the human body. Advances in the field of light delivery to internal areas of the body allow delivery to organs and other areas without the need for any extensive surgical procedures.
• the activation process can be extremely site specific, as the direction of a laser beam can be controlled with great precision, and the beam diameter can be reduced far below that of a single cell, minimising any possible damage to other neighbouring tissue from unwanted activation of the drug.
• the high energy of ultra-violet light e.g. 350 nm equivalent to 340 kJ/mol
• a further class of prodrugs is those where the protecting group is removed by an enzyme naturally present at the desired site of action.
• These enzymes include dopa-decarboxylase, L- ⁇ -glutamyl transpeptidase, and mixed function oxidases and reductase (e.g. DT-diaphrase) .
• This is method termed "naturally present enzyme- prodrug therapy (NPEPT) in this application.
• NPEPT enzyme- prodrug therapy
• One enzyme of particular interest is glutathione transferase (GST) , which forms part of a major cellular defence mechanism based on the use of the tripeptide, glutathione, as a scavenger of toxic electrophiles .
• GST acts as a catalyst in the reaction between glutathione and its target electrophiles.
• Prodrugs which make use of this elevated GST level have been made (Satyam et al . , Med. Chem. 1996, 39, 1736-1747). They have a glutathione molecule linked via a 2-sulphonylethyloxycarbonyl linker to a phosphorodiamidate mustard.
• An alternative type of prodrug has made use of the closely related 2- phenylsulphonylethyloxycarbonyl (Psec) group (Nicolaou et al . ,
• Such prodrugs showed selectivity between healthy human bone marrow cells and promeocytic and T cell leukemia tumour lines.
• R 10 is a therapeutically removable nitrogen protecting group
• R CH 2 , CH 2 -C0 2 R, CH 2 -C0 2 H, CH 2 -S0 2 R, 0-S0 2 -R, C0 2 R, COR and CN;
• R ⁇ , R 7 and R 9 are independently selected from H, R, OH, OR, halo, amino, nitro, Me 3 Sn; or R 7 and R 8 together form a group
• X is S, O or NH
• Ri is either H or R; where R is a lower alkyl group having 1 to 10 carbon atoms, or an aralkyl group (i.e. an alkyl group with one or more aryl substituents ) , preferably of up to 12 carbon atoms, whereof the alkyl group optionally contains one or more carbon-carbon double or triple bonds, which may form part of a conjugated system, or an aryl group, preferably of up to 12 carbon atoms; and is optionally substituted by one or more halo, hydroxy, amino, or nitro groups, and optionally contains one or more hetero atoms, which may form part of, or be, a functional group; and where there is optionally a double bond between Cl and C2 or C2 and C3; and R 8 is selected from H, R, OH, OR, halo, amino, nitro, Me 3 Sn, where R is as defined above, or the compound is a dimer with each monomer being the same or different and being of formula I, where the R 8
• R is an aryl group, and contains a hetero atom
• R is a heterocyclic group.
• the hetero atom may be located anywhere in the alkyl chain, e.g. -0-C 2 H 5 , -CH 2 -S-CH 3 , or may form part of, or be, a functional group, e.g. carbonyl, hydroxy.
• R is preferably independently selected from a lower alkyl group having 1 to 10 carbon atoms, or an aralkyl group, preferably of up to 12 carbon atoms, or an aryl group, preferably of up to 12 carbon atoms, optionally substituted by one or more halo, hydroxy, amino, or nitro groups. It is more preferred that R groups are independently selected from a lower alkyl group having 1 to 10 carbon atoms optionally substituted by one or more halo, hydroxy, amino, or nitro groups. It is particularly preferred that R groups are unsubstituted straight or branched chain alkyl groups, having 1 to 10, preferably 1 to 6, and more preferably 1 to 4, carbon atoms, e.g. methyl, ethyl, propyl, butyl.
• R 6 , R 7 , R 8 , and R 9 may preferably be independently selected from R groups with the following structural characteristics:
• 'electron sink' means a moiety covalently attached to a compound which is capable of reducing electron density in other parts of the compound.
• electron sinks include cyano, carbonyl and ester groups.
• 'therapeutically removable nitrogen protecting group means any group which can protect the 10-nitrogen, but which is removable under therapeutic conditions in vivo, that is, removable under conditions which occur or can be caused to occur in vivo and are medically acceptable generally by elimination to produce a N10-C11 imine group or an equivalent, capable of interacting with DNA. The removal of the protecting group should leave the rest of the structure of the PBD unaffected.
• Suitable removal techniques include applying light, e.g. with a wavelength of 250 to 400, or 550 nm, changing the ambient pH, or cleavage by the action of an enzyme.
• One particularly suitable enzyme is nitroreductase, although other suitable enzymes include penicillin V/G amidase, ⁇ -lactamase, phosphatase, L- ⁇ -glutamyl transpeptidase, and ⁇ -galactosidase .
• the action of some of these enzymes is described in Jungheim, L.N. and Shepherd, T.A., Design of Antitumour Prodrugs: Substrates for Antibody Targeted Enzymes, Am. Chem . Soc . Chem . Rev. , 1994, 94: 6, 1553 - 1566.
• Another particularly suitable enzyme is glutathiffe transferase, as discussed above.
• R 10 of the formula II is R 10 of the formula II:
• R (I) is H or R
• R (II) is one or more optional substituents independently selected from N0 2 , OR, or R, where R is as defined in any of the definitions above; and if two substituents R (II) are on adjacent atoms, they may together be of the formula -O- (CH 2 ) m -0-, where m is 1 or 2.
• R (II) is preferably N0 2 .
• therapeutically removable group R 10 is one which is susceptible to nitroreductase, it may be of the formula III:
• R (III) is one or more optional substituents independently selected from N0 2 , OR or R, where R is as defined in any of the definitions above, and if two substituents R (ni) are on adjacent atoms, they may together be of the formula - O - (CH 2 ) m -0-, where m is 1 or 2.
• R 10 Another possible therapeutically removable nitrogen protecting group, R 10 , is of the formula XI:
• R is as defined in any of the definitions above and n is 0 to 3, preferably 0.
• R is most preferably a phenyl group, substituted or unsubstituted.
• This protecting group may be removable by the action of glutathione transferase (GST) , which is present at high levels in many human tumour cells (see above) .
• R 6 and R 9 are H, and further preferred that R 7 and R a are independently selected from H, OH, and OR. It is further preferred that R 2 and R 3 are H.
• the dimer bridge may be of the formula -O- (CH 2 ) p -0-, where p is from 1 to 12, preferably 3 to 9. Further, R 6 and R 9 are preferably H, and R 7 is preferably independently selected from H, OH, and OR.
• a product in which XR n is OR may be prepared by direct etherification of compound la.
• a product in which X is S may be prepared by treatment of compound la with R U SH and a catalyst (generally a Lewis acid such as A1 2 0 3 ) .
• a product in which X is NH may be prepared by treatment of compound la with an amine R ln NH and a catalyst (generally a Lewis acid such as A1 2 0 3 ) .
• a third aspect of the present invention provides a method of preparing a compound of formula la as described in the second aspect of the invention, by the oxidation of a compound of formula IVa:
• a fourth aspect of the present invention provides a method of preparing a compound of formula IVa as described in the third aspect of the invention, by reacting a compound of formula Va:
• the compound of formula VI is a haloformate of the formula Via:
• the compound of formula VI is a haloformate of the formula VIb: O 00/12507
• a fifth aspect of the present invention provides an alternative synthesis of a compound of formula IVa as described in the third aspect of the invention, by reacting a compound of formula VII:
• a sixth aspect of the present invention provides a method of preparing a compound of formula la as described in the second aspect of the invention, by the unmasking of a compound of formula IVb:
• a seventh aspect of the present invention provides a method of preparing a compound of formula IVb as described in the sixth aspect of the invention, by reacting a compound of formula Vb :
• the compound of formula VI is a haloformate of the formula Via:
• An eighth aspect of the present invention provides an alternative synthesis of a compound of formula IVb as described in the second aspect of the invention, by reacting a compound of formula VII:
• a ninth aspect of the present invention provides a method of making a compound of formula X:
• a tenth aspect of the present invention provides a use of a compound of formula I, wherein the therapeutically removable nitrogen protecting group (R 10 )is enzyme labile, in conjunction with an appropriate enzyme in methods of ADEPT or GDEPT therapy. If the enzyme labile group is susceptible to nitroreductase, then compounds of formula I, may be used in conjunction with nitroreductase enzymes (for example, those isolated from E. coli ) in methods of ADEPT and GDEPT therapy.
• An eleventh aspect of the present invention provides a use of a compound of formula I, wherein the therapeutically removable nitrogen protecting group (R 10 )is photolabile, in conjunction with light of wavelengths between 250 and 400 or 550 nm in methods of PDT.
• a twelfth aspect of the invention provides a use for a compound of formula I, where the therapeutically removable nitrogen protecting group (R 10 ) is labile by conditions occurring naturally at specific localised sites in the patient in therapy.
• Suitable compounds of formula I may be those susceptible to a nitroreductase enzyme when used to treat hypoxic tumour cells, or those susceptible to enzymes which are naturally occurring at specific localised sites, such as glutathione transferase.
• the drug produced by the cleavage of the therapeutically removable nitrogen protecting group may be used for treating cancers or other site-specific diseases where a local increase of toxicity is beneficial to the patient.
• Cancers that may be treated are solid cancers including ovarian, colonic cancer, renal, breast and bowel CNS, melanoma, as well as leukemias .
• Such drugs may also be suitable for treating bacterial, viral or parasitic infections by exploiting a unique enzyme produced at the site of the infection which is not natural to the host, or by exploiting an elevation in the amount of an enzyme which does naturally occur in the host.
• a thirteenth aspect of the present invention is a pharmaceutical composition comprising a compound of formula I as described in the first aspect of the invention.
• Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention may comprise, in addition to the active ingredient, i.e. a compound of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
• the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.
• compositions for oral administration may be in tablet, capsule, powder or liquid form.
• a tablet may comprise a solid carrier or an adjuvant.
• Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
• Capsules may comprise a solid carrier such as gelatin.
• the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
• a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
• Suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
• Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
• a fourteenth aspect of the present invention provides the use of a compound of formula I as described in the first aspect of the invention, to prepare a medicament for the treatment of neoplastic disease or other site-specific diseases where a local increase of toxicity is beneficial to the patient.
• the compound of formula I may be provided together with a pharmaceutically acceptable carrier or diluent.
• the preparation of a medicament is described in relation to the thirteenth aspect of the invention.
• Fig. 1 is a synthesis scheme according to the present invention
• Figs. 2a & 2b are a synthesis scheme for dimers according to the present invention
• Fig. 3 is a synthesis scheme showing an alternative cyclisation, for use in the present invention
• Fig. 4 is a graph illustrating the cytotoxicity results for prodrug compound 7 (see example 1), both before and after activation with nitroreductase/NADH in SW1116 cells and LS174T cells
• Fig. 5 is a graph illustrating the percentage of compound 11 (see example 3) cleaved by UVA (365 nm) exposure over a 3 hour time course;
• Fig. 6 is a graph illustrating the in vi tro cytotoxicity (IC S0 ; ⁇ M) of benzyl DC-81 and compound 11, with varying irradiation times, against human chronic myeloid leukaemia K562 cells in DMF at 1 mM initial drug concentration;
• Fig. 7 is a graph illustrating the in vi tro cytotoxicity (IC S0 ; ⁇ M) of benzyl DC-81 and compound 11, with varying irradiation times, against human chronic myeloid leukaemia K562 cells in DMF at 10 mM initial drug concentration;
• Fig. 8 is a graph illustrating the in vi tro cytotoxicity (IC 50 ; ⁇ M) of benzyl DC-81 and compound 11, with varying irradiation times, against human chronic myeloid leukaemia K562 cells in methanol at a 1 mM initial drug concentration
• Fig. 9 is a graph illustrating the in vi tro cytotoxicity (IC 50 ; ⁇ M) of DSB-120 and compound 32, with varying irradiation times, against human chronic myeloid leukaemia K562 cells in methanol at a 1 mM initial drug concentration.
• a key step in a preferred route to compounds of formula I is a cyclisation to produce the B-ring, involving generation of an aldehyde (or functional equivalent thereof) at what will be the 11-position, and attack thereon by the 10-nitrogen:
• the masked aldehyde may be an aldehyde precursor, such as an alcohol, -CHOH, in which case the reaction involves oxidation, e.g. by means of TPAP or DMSO (Swern oxidation) .
• the masked aldehyde compound can be produced by condensing a corresponding 2-substituted pyrrolidine with a 2-nitrobenzoic acid:
• nitro group can then be reduced to -NH 2 and protected by reaction with a suitable agent, e.g. a chloroformate, which provides the therapeutically removable nitrogen protecting group
• FIG. 1 A process involving the oxidation-cyclization procedure is illustrated in Figure 1 (an alternative type of cyclisation will be described later with reference to Figure 3) .
• R xl is other than hydrogen
• the compound of formula I may be prepared by direct etherification of the alcohol la.
• X is NH then treatment of the alcohol la with the appropriate amine yields the desired compound of formula I.
• the uncyclized alcohol (IVa) may be prepared by the addition of a nitrogen protection reagent of formula VI, which is preferably a chloroformate or acid chloride, to the amino alcohol (Va) , generally in solution, generally in the presence of a base such as pyridine (preferably 2 equivalents) at a moderate temperature (e.g. at 0°C) . Under these conditions little or no O-acylation is usually observed.
• a nitrogen protection reagent of formula VI which is preferably a chloroformate or acid chloride
• the key amino alcohol (Va) may be prepared by reduction of the corresponding nitro compound (Xla) , by choosing a method which will leave the rest of the molecule intact.
• Exposure of Xla to hydrazine/Raney nickel avoids the production of tin salts and may result in a higher yield of Va, although this method is less compatible with the range of possible C and A-ring substituents. For instance, if there is C-ring unsaturation (either in the ring itself, or at R 2 or R 3 ) , this technique may be unsuitable.
• the nitro compound of formula Xla may be prepared by coupling the appropriate o-nitrobenzoyl chloride to a compound of formula IXa, e.g. in the presence of K 2 C0 3 at -25 °C under a N 2 atmosphere.
• the o-nitrobenzoyl chloride is synthesised from the o-nitro benzoic acid of formula XII - many of these are commercially available, and the synthesis of some examples has been reported by Althuis (Althuis, T.H. and Hess, H-J, 1977, Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat,
• PBD dimers may be synthesized using the strategy developed for the synthesis of the protected PBD monomers ( Figure 2a).
• Figure 2 also shows a synthesis route where the dimer linkage is of the formula -O- (CH 2 ) n -0- .
• the step of dimer formation is normally carried out to form a bis (nitro acid) XII' ( Figure 2b).
• the bis (nitro acid) XII 1 may be obtained by nitrating (e.g. using 70% nitric acid) the bis (carboxylic acid). This can be synthesised by alkylation of two equivalents of the relevant benzoic acid with the appropriate diiodoalkane under basic conditions (Route 2a) . Many benzoic acids are commercially available and others can be synthesised by conventional methods.
• An alternative synthesis of the bis (nitro acid) involves oxidation of the bis (nitro aldehyde), e.g. with potassium permanganate. This can be obtained in turn by direct nitration of the bis (aldehyde) , e.g. with 70% HN0 3 . Finally, the bis (aldehyde) can be obtained via Mitsunobu etherification of two equivalents of the benzoic aldehyde with the appropriate alkanediol (Route 2b) .
• the final or penultimate step is an oxidative cyclisation.
• An alternative, using thioacetal coupling unmasking, is shown in figure 3 (which shows it applied to a dimer, with a dimer linkage of formula -o- (CH 2 ) n -0-) .
• Mercury- mediated unmasking causes cyclisation to the desired compound (la' ) .
• the thioacetal compound may be prepared as shown in figure 3: the thioacetal protected C-ring [prepared via a literature method: Langley, D.R. & Thurston, D.E., J. Organi c Chemistry, 52, 91-97 (1987)] is coupled to the bis (nitro carboxylic acid) core using a literature procedure.
• the resulting nitro compound cannot be reduced by hydrogenation, because of the presence of the thioacetal group, so the tin (II) chloride method is used to afford the bis(amine).
• This is then N-protected, e.g., by reaction with a chloroformate or acid chloride, such as p- nitrobenzylchloroformate .
• Acid or palladium-mediated unmasking is the preferred method of unmasking to cause cyclisation to the desired compound of formula la or I' a.
• the vector for use in GDEPT therapies may be any suitable DNA or RNA vectors.
• Suitable non-viral vectors include cationic liposomes and polymers.
• Suitable viral vectors include those which are based upon a retrovirus . Such vectors are widely available in the art. Huber et al . (ibid) report the use of amphotropic retroviruses for the transformation of hepatoma, breast, colon or skin cells. Culver et al . (Science (1992) 256; 1550-1552) also describe the use of retroviral vectors in GDEPT. Such vectors or vectors derived from them may also be used. Other retroviruses may also be used to make vectors suitable for use in the present invention. Such retroviruses include Rous sarcoma virus (RSV) .
• RSV Rous sarcoma virus
• Englehardt et al . (Nature Genetics (1993) 4.; 27-34) describe the use of adenovirus-based vectors in the delivery of the cystic fibrosis transmembrane conductance product (CFTR) into cells, and such adenovirus-based vectors may also be used.
• Vectors utilising adenovirus promoter and other control sequences may be of use in delivering a system according to the invention to cells in the lung, and hence useful in treating lung tumours.
• vectors based on the Molony murine leukaemia virus are known (Ram, Z et al . , Cancer Research (1993) 53; 83-88; Dalton & Treisman, Cell (1992) 68.; 597-612) .
• These vectors contain the Murine Leukaemia virus (MLV) enhancer cloned upstream at a ⁇ -globin minimal promoter.
• MLV Murine Leukaemia virus
• the ⁇ -globin 5' untranslated region up to the initiation codon ATG is supplied to direct efficient translation of the enzyme.
• Suitable promoters which may be used in vectors described above, include MLV, CMV, RSV and adenovirus promoters.
• Preferred adenovirus promoters are the adenovirus early gene promoters . Strong mammalian promoters may also be suitable.
• An example of such a promoter is the EF-l ⁇ promoter which may be obtained by reference to Mizushima and Nagata ((1990), Nucl . Acids Res. 18; 5322). Variants of such promoters retaining substantially similar transcriptional activities may also be used.
• promoters include tissue specific promoters, and promoters activated by small molecules, hypoxia or X-rays.
• nitroreductase is the enzyme of choice for the activation of compounds of formula I
• the enzyme is a non- mammalian nitroreductase such as a bacterial nitroreductase .
• An E. coli nitroreductase as disclosed in WO93/08288 is particularly preferred.
• the enzyme may be modified by standard recombinant DNA techniques, e.g. by cloning the enzyme, determining its gene sequence and altering the gene sequence by methods such as truncation, substitution, deletion or insertion of sequences for example by site-directed mutagenesis. Reference may be made to "Molecular Cloning" by Sambrook et al .
• the modification made may be any which still leaves the enzyme with the ability to reduce the nitro group in suitable compounds of formula I, but alters other properties of the enzyme, for example its rate of reaction or selectivity.
• small truncations in the N- and/or C-terminal sequence may occur as a result of the manipulations required to produce a vector in which a nucleic acid sequence encoding the enzyme is linked to the various other vector sequences .
• an antibody directed against a tumour specific marker is linked to the relevant enzyme, which may be modified as described above.
• the antibody may be monoclonal or polyclonal.
• the term "antibody”, unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a tumour target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies.
• the antibodies and fragments thereof may be humanised antibodies, e.g. as described in EP-A-239400.
• the antibodies may be produced by conventional hybridoma techniques or, in the case of modified antibodies or fragments, by recombinant DNA technology, e.g. by the expression in a suitable host vector of a DNA construct encoding the modified antibody or fragment operably linked to a promoter.
• suitable host cells include bacterial (eg. E. coli ) , yeast, insect and mammalian cells.
• the enzyme may be produced by linking a nucleic acid sequence encoding the enzyme (optionally modified as described above) to the 3' or 5 ' end of the sequence of the construct encoding the antibody or fragment thereof.
• the activation process in PDT can be highly site specific.
• the direction of a laser beam can be controlled with great precision, and the beam diameter can be reduced to a width far below that of a single cell. Therefore, it can act upon a very limited area, minimising damage to neighbouring tissue.
• Ultra-violet light is sufficient to break a range of chemical bonds since the energy spectrum for bond breakage for the majority of organic molecules lies between 250 and 420 kJ/mol, and, for example, 350 nm is equivalent to 340 kJ/mol.
• a broad range of light-mediated deprotection reactions have been demonstrated including the photochemical deprotection of amino acids, peptides and polysaccharides from their CBZ and o-nitrobenzyl and , 5-dimethoxy-2-nitrobenzyl carbamate forms at wavelengths longer than 350 nm, (Pillai, R. V. N., Photoremovable protecting groups in organic chemistry, Synthesis (1980), 1-26), (Bayley, H., Gasparro, F.
• tumour types have been identified as potential targets for PDT. They include head and neck tumours, carcinomas of the bronchus, malignant brain tumours, superficial tumours of the bladder and vascular disease, which have all shown promising responses in the clinic, (Regula, J., Mac Roberts, A. J. , Gorchein, A., Buonaccorsi, Thorpe, S. M. , Spencer, G. M. , Hartfield, A. R. . and Bown, S. G., Photosensitisation and photodynamic therapy of oesophageal, duodenal and colorectal tumours using 5-aminoleavulic acid induced protoporphyrin IX-a pilot study, Gut (1995) 36, 67-75).
• the technique of PDT as discussed above can be used in combination with appropriate compounds of formula I when the therapeutically removable nitrogen protecting group is photolabile.
• the preferred wavelength of UV light used is 250 to 400 or 550 nm.
• Compounds of the invention can be used in vi tro or in vivo for a range of applications.
• a number of vector systems for the expression of nitroreductase in a cell have been developed.
• the further development of such systems e.g. the development of promoters suitable for specific cell types
• suitable candidate prodrugs capable of killing cells when activated by nitroreductase e.g. the development of promoters suitable for specific cell types
• Prodrug compounds of formula I susceptible to nitroreductase may be used in such model systems.
• the model systems may be in vi tro model systems or in vivo xenograft model systems comprising for example human tumour cells implanted in nude mice.
• Compounds of formula I susceptible to different enzymes may be used in similar systems which have been appropriately modified.
• Compounds of formula I which are not activatable by an enzyme may be tested in vi tro with other suitable forms of activation against panels of different tumour cell types to determine efficacy against such tumour cells.
• the efficacy of compounds of the invention against a range of tumour cell types may be used as points of reference for the development of further antitumour compounds.
• Compounds of formula I may also be tested in combination with additional anti-cancer compounds to determine potential combination drug systems, for example combinations which are synergistic.
• Compounds of formula I may also be used in a method of treatment of the human or animal body.
• Such treatment includes a method of treating the growth of neoplastic cells in a patient with neoplastic disease which comprises administering to a patient in need of treatment compounds of formula I as part of an ADEPT, GDEPT or PDT system or treatment with compounds of formula I alone, where neoplastic diseases include leukaemia and solid tumours such as ovarian, colonic, lung, renal, breast, bowel, CNS and melanomas.
• the treatment can also be the treatment of other site-specific diseases where local increase in toxicity is beneficial to the patient.
• treatment includes any measure taken by the physician to alleviate the effect of the tumour on a patient.
• effective treatment will also include any measures capable of achieving partial remission of the tumour as well as a slowing down in the rate of growth of a tumour including its metastases. Such measures can be effective in prolonging and/or enhancing the quality of life and relieving the symptoms of the disease.
• the antibody/enzyme conjugate for ADEPT can be administered simultaneously but it is often found preferable, in clinical practice, to administer the enzyme/antibody conjugate before the prodrug, e.g. up to 72 hours or even 1 week before, in order to give the enzyme/antibody conjugate an opportunity to localise in the region of the tumour target.
• the prodrug is administered, conversion of the prodrug to the cytotoxic agent tends to be confined to the regions where the enzyme/agent conjugate is localised, i.e. the region of the target tumour. In this way, the premature release of the compound produced by the action of the nitroreductase on the prodrugs of the present invention is minimised.
• the degree of localisation of the enzyme/agent conjugate (in terms of the ratio of localized to freely circulating active conjugate) can be further enhanced using the clearance and/or inactivation systems described in WO89/10140.
• a component may include an antibody to the enzyme component of the system which is capable of inactivating the enzyme.
• the second component may be linked to a macromolecule such as dextran, a liposome, albumin, macroglobulin or a blood group O erythrocyte so that the second component is restrained from leaving the vascular compartment.
• the second component may include a sufficient number of covalently bound galactose residues, or residues of other sugars such as lactose or mannose, so that it can bind the conjugate in plasma but be removed together with the conjugate from plasma by receptors for galactose or other sugars in the liver.
• the second component should be designed for use and administered such that it will not, to any appreciable extent, enter the extravascular space of the tumour where it could inactivate localised conjugate prior to and during administration of the prodrug.
• the dose of the prodrug and conjugate will ultimately be at the discretion of the physician, who will take into account such factors as the age, weight and condition of the patient. Suitable doses of prodrug and conjugate are given in Bagshawe et al . Antibody, Immunoconjugates, and Radiopharmaceuticals (1991), 4 . , 915-922.
• a suitable dose of conjugate may be from 500 to 200,000 enzyme units/m 2 (e.g. 20,000 enzyme units/m 2 ) and a suitable dose of prodrug may be from about 0.1 to 200 mg/Kg, preferably from about 10 to about 100 mg/Kg per patient per day.
• the ADEPT system when used with nitroreductase also preferably comprises a suitable co-factor for the enzyme. Suitable co- factors may include a riboside or ribotide of nicotinic acid or nicotinamide .
• the antibody/enzyme conjugate may be administered by any suitable route usually used in ADEPT therapy. This includes parenteral administration of the antibody in a manner and in formulations similar to that described below.
• the vectors will usually be packaged into viral particles and the particles delivered to the site of the tumour, as described in for example Ram et a 1 . ( supra ) .
• the viral particles may be modified to include an antibody, fragment thereof (including a single chain) or tumour- directed ligand to enhance targeting of the tumour.
• the vectors may be packaged into liposomes .
• the liposomes may be targeted to a particular tumour. This can be achieved by attaching a tumour-directed antibody to the liposome.
• Viral particles may also be incorporated into liposomes.
• the particles may be delivered to the tumour by any suitable means at the disposal of the physician.
• the viral particles will be capable of selectively infecting the tumour cells.
• selectively infecting it is meant that the viral particles will primarily infect tumour cells and that the proportion of non- tumour cells infected is such that the damage to non-tumour cells by administration of a prodrug will be acceptably low, given the nature of the disease being treated. Ultimately, this will be determined by the physician.
• Viruses for example isolated from packaging cell lines, may also be administered by regional perfusion or direct intratumoral injection, or direct injection into a body cavity (intracaviterial administration) , for example by intra-peritoneal injection.
• the exact dosage regime for GDEPT will, of course, need to be determined by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of the prodrug and the cytotoxic agent to be released from the prodrug. However, some general guidance can be given.
• Chemotherapy of this type will normally involve parenteral administration of modified virus, and administration by the intravenous route is frequently found to be the most practical.
• the amount of virus or other vector delivered will be such as to provide a similar cellular concentration of enzyme as in the ADEPT system mentioned above.
• the vector will be administered to the patient and then the uptake of the vector by transfected or infected (in the case of viral vectors) cells monitored, for example by recovery and analysis of a biopsy sample of targeted tissue. This may be determined by clinical trials which involve administering a range of trial doses to a patient and measuring the degree of infection or transfection of a target cell or tumour.
• the amount of prodrug required will be similar to or greater than that for ADEPT systems.
• prodrug In using a GDEPT system the prodrug will usually be administered following administration of the vector encoding an enzyme. Suitable doses of prodrug are from about 0.1 to 200 mg/Kg, preferably from about 10 to about 100 mg/Kg per patient per day.
• the formulations comprise the compounds, together with one or more acceptable carriers thereof and optionally other therapeutic ingredients, or diluents.
• the carrier or carriers must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof, for example, liposomes.
• Suitable liposomes include, for example, those comprising the positively charged lipid (N [1- (2 , 3-dioleyloxy) propyl] -N, N, N-triethylammonium (DOTMA) , those comprising dioleoylphosphatidylethanolamine (DOPE), and those comprising 3 ⁇ [N- (n'N' -dimethylaminoethane) - carbamoyl] cholesterol (DC-Choi).
• DOTMA positively charged lipid
• DOPE dioleoylphosphatidylethanolamine
• DC-Choi 3 ⁇ [N- (n'N' -dimethylaminoethane) - carbamoyl] cholesterol
• Formulations suitable for parenteral or intramuscular administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bacteriocidal Antibiotics and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs .
• the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example Water for Injection, immediately prior to use.
• a sterile liquid carrier for example Water for Injection
• Injection solutions and suspensions may be prepared extemporaneously from sterile powders, granules and tablets of the kind previously described.
• the formulations may include other agents conventional in the art having regard to the type of formulation in question.
• sterile pyrogen-free aqueous and non-aqueous solutions are preferred.
• the doses may be administered sequentially, eg. at hourly, daily, weekly or monthly intervals, or in response to a specific need of a patient.
• Preferred routes of administration are oral delivery and injection, typically parenteral or intramuscular injection or intratumoural injection.
• parenteral or intramuscular injection or intratumoural injection may be preferred, e.g. subcutaneous injection or creams and ointments, and such methods of administration are well known.
• the exact dosage regime will, of course, need to be determined by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of the compound of formula I, but some general guidance can be given. Typical dosage ranges generally will be those described above which may be administered in single or multiple doses. Other doses may be used according to the condition of the patient and other factors at the discretion of the physician.
• HRMS Accurate molecular masses
• PFK perfluorokerosene
• FAB mass spectra were obtained from a glycerol/thioglycerol/ trifluoroacetic acid (1:1:0.1) matrix with a source temperature of 180°C.
• Optical rotations at the Na-D line were obtained at ambient temperature using a Perkin-Elmer 141 Polarimeter.
• Flash chromatography was performed using Aldrich flash chromatography "Silica Gel-60" (E. Merck, 230-400 mesh).
• Thin-layer chromatography (TLC) was performed using GF 254 silica gel (with fluorescent indicator) on glass plates.
• Example 1 Synthesis of a nitroreductase-activated benzyl DC-81 prodrug for ADEPT (7) .
• Method B 4-benzyloxy-3-methoxybenzoic acid (8.5g, 32.9 mmol) was added in small portions over 30 minutes to stirred solution of 70% nitric acid (100 ml) . When addition was complete the reaction mixture was allowed to warm to 15 °C and maintained at that temperature for a further 30 min. The reaction mixture was then poured onto ice and the resultant precipitate was collected by filtration, washed with ice-cold water and dried to afford the nitrated product 3 as a yellow powder.
• the resulting acid chloride solution was then added dropwise over 30 minutes to a stirred suspension of pyrrolidinemethanol (1.168 g, 11.56 mmol, 1 eq) and K 2 C0 3 (3.675 g, 26.63 mmol, 2.3 eq) in acetonitrile (80 ml) at -25°C under a nitrogen atmosphere.
• the reaction mixture was stirred at the same temperature for a further 1 hour and then allowed to return to room temperature and quenched with water (200 ml) .
• Method B Hydrazine hydrate (4.53 g, 90.67 ml, 5 eq) was added dropwise to a solution of the nitro compound 4 (7.0 g, 18.13 mmol) in dry methanol (20 ml) and a catalytic amount of Raney Ni (0.544 g) over antibumping granules whilst a gently reflux was maintained. The mixture was heated at reflux for a further 15 minutes when TLC (5% MeOH/CHCl 3 ) indicated that the reaction had gone to completion. The Ni catalyst was then removed by filtration through Celite and the solvent removed by evaporation in vacuo. The product was further purified by flash chromatography (5% MeOH/CHCl 3 ) to afford the amine 5 as a bright yellow unstable oil which required storage at low temperature.
• TPAP (23 mg, 10% molar) was then added to the reaction mixture and it was allowed to stir for a further 2 hours when the reaction was found to be complete by TLC (2% MeOH/CHCl 3 ) .
• the molecular sieve was removed by filtration through Celite and the resulting solution was evaporated in vacuo .
• the resulting dark oil was subjected to flash chromatography (1% MeOH/CHCl 3 ) to give the photolabile protected PBD (11) .
• Tributyltinhydride (1.49 g, 5.1 mmol, 1.1 eq) was added to a solution of 18 (1.5 g, 4.62 mmol) in DCM (30 ml) in the presence of water (0.48 g, 27.11 mmol, 6 eq) and a catalytic amount of Pd(PPh 3 ) 2 Cl 2 (0.132 g, 0.189 mmol, 4% molar) and the reaction mixture was allowed to stir for 5 minutes at room temperature.
• TPAP (9.4 mg, 0.026 mmol, 5% molar) was then added and the mixture was allowed to stir under the same conditions for a further 2.5 hours.
• the reaction mixture was filtered through Celite and the filtrate evaporated in vacuo .
• the residue was subjected to flash chromatography (1% MeOH/CHCl 3 ) to obtain the target compound (24).
• the dimer acid 25 (5 g, 13.3 mmol) was added slowly in small portions over 30 minutes to a stirred solution of 70% HN0 3 (50 ml) at 0°C. After the addition was complete the reaction mixture was allowed to warm to 15 °C and stirring continued for a further 2 hours. The reaction mixture was poured onto ice causing precipitation of the product. The yellow precipitate was collected by filtration, washed with cold water and dried to afford the nitrated dimer acid core (26) as a pale yellow solid. Yield 4.52 g (73%); mp. 241-246°C; IR (cm "1 ) 3500-3200, 2924, 1713, 1604, 1582, 1523, 1459, 1377, 1282, 1218, 1189, 1053; X E-
• the resulting mixture was allowed to stir at -25°C for a further 1.5 hour when the reaction mixture was diluted with water (100 ml) .
• the solution was then extracted with chloroform (4 x 100 ml) .
• the combined organic phase was washed with aq. IM HCl (2 x 75 ml) , water (2 x 75 ml) , brine (100 ml), dried (MgS0 4 ) and evaporated in vacuo .
• the resulting orange oil was purified by column chromatography (10% MeOH/CHCl 3 ) to afford the pure product 27 as a yellow viscous oil.
• the reaction mixture was diluted with chloroform (50 ml) and washed with a saturated aqueous solution of CuS0 4 (2 x 50 ml), water (2 x 50 ml), brine (100 ml) and dried (MgS0 4 ) .
• the organic solvent was removed in vacuo and the pure dimer carbamate 29 was obtained after flash chromatography (7% MeOH/CHCl 3 ) as a bright yellow foam.
• TPAP (13.4 mg, 0.114 mmol, 0.3 eq) was added in one portion to a solution of the bis carbamate 29 (0.35 g, 0.37 mmol) and NMO (0.134 g, 1.14 mmol, 3.1 eq) in dry DCM/CH 3 CN (9:3 ml) which has been allowed to stir over molecular sieve (0.350 g) for 15 minutes under N 2 and at room temperature. Progress of the reaction was followed by TLC (7% MeOH/CHCl 3 ) . After 2 hours reaction was still incomplete requiring the addition of a further amount of NMO (67 mg, 0.55 mmol, 1.5 eq) and TPAP (6.7 mg, 0.05 mmol, 0.15 eq) .
• 57 intensity 925 (M + -l, 1), 889 (5), 711 (6), 501 (3), 286 (10), 252 (7), 213 (15), 192 (32), 197 (11), 185 (22), 181 (42), 165 (15), 149 (47), 131 (18), 119 (16), 105 (29), 91 (96), 73 (100), 57 (54) .
• reaction mixture was then diluted with chloroform (50 ml) and washed with saturated aqueous solution of CuS0 4 (2 x 50 ml), water (2 x 50 ml), brine (100 ml) and dried (MgS0 4 ) . Removal of the solvent under reduced pressure gave a dark yellow oil which was further purified by flash chromatography (7% MeOH/CHCl 3 ) to afford the pure product as a yellow foam.
• NMO (0.138 g, 1.16 mmol, 3.1 eq) and molecular sieve (350 mg) was added to a stirred solution of the NVOC dimer carbamate 31(0.4 g, 0.38 mmol) in dry DCM and acetonitrile (9:3 ml) under nitrogen. This mixture was allowed to stir for 15 minutes before the addition of TPAP (13.8 mg, 0.116 mmol, 0.3 eq) .
• Triphenylphosphine oxide was removed by filtration and the filtrate was washed with NaOH (100 ml), dried (MgS0 4 ) , evaporated in vacuo and the remaining opaque oil was purified by flash chromatography (100% CHC1 3 ) to afford a white solid.
• the dimer aldehyde (39) (5 g, 14.5 mmol) was added in small portions over a period of 30 minutes to HN0 3 (100 ml, 70%) at 0°C. The resulting suspension was stirred for a further 30 minutes at 15 °C when it was poured onto ice-water and the bright yellow precipitate was collected by filtration, washed with cold water and dried to afford the nitrated intermediate.
• Lithium tetrahydroborate (2.6 g, 0.12 mol) was added portionwise to a solution of N-carbobenzyloxy-L-proline methyl ester 41 (21 g, 0.08 mol) in THF (500 ml) at 0°C. The reaction mixture was allowed to stir at room temperature for 48 hours. The solution was then cooled to 0°C and ice water (150 ml) was added to quench excess lithium tetrahydroborate. The resulting suspension was adjusted to pH 4.0 with aqueous HCl (1.0 N) and extracted with Et 2 0 (250 ml) .
• Nickel 0.1 g
• Nickel was removed by filtration through Celite.
• SW1116 and LS174T are human adenocarcinoma colonic cell lines, which were grown at Charing Cross hospital.
• the cells at a concentration of 2500 cells/ml, were plated in 96-well microtitre plates, and were incubated at 37°C for 1 hour with different concentrations of the prodrug, in the presence or absence of E. coli nitroreductase-monoclonal antibody conjugate in phosphate buffer saline (available from Sigma) , and NADH (the co-factor necessary for enzyme function) in DMSO.
• the cells were then washed and incubated for a further 3 days at 37 °C. At the end of this period, the cells were fixed (TCA) and stained. The concentration of the remaining viable cells adhering to the plates was quantified by a sulforhodamine B (SRB) dye.
• SRB sulforhodamine B
• the parent drug, benzyl DC-81 (Thurston et al, 1990, Chem. Bri t . , 26, 767-772) , was also evaluated in the same cell lines under the same conditions in order to establish the extent of activation 00/12507
• Compound 24 was examined in the same cell lines as example 6, and under the same conditions. It exhibited an IC 50 value of 86.2 ⁇ M (average of two experiments) which, after addition of the enzyme conjugate and NADH, dropped to 6.4 ⁇ M, indicating an activation factor of approximately 13.5. In this case, the parent benzyl tomaymycin was unavailable for evaluation as a control. However, assuming that the addition of a benzyl group to the C8-position of the A-ring of tomaymycin does not change the cytotoxicity of the compound significantly (as is the case for DC-81/C8-benzyl DC-81), the cytotoxicity of C8-benzyl tomaymycin should be in the order of 0.01-0. OOl ⁇ M.
• Example 10 Light-activation of the benzyl DC-81 prodrug (Compound 11)
• This experiment involved the irradiation of compound 11, see example 3, in DMF at a concentration of 1 mM using a Stratagene UVA Crosslinker (365 nm) .
• Small aliquots (lOO ⁇ L) were removed at 30 minutes, 1 hour, 2 hours and 3 hours and the cleavage of the photolabile NVOC group was monitored by HPLC, using a Waters C4, 300 angstrom reversed phase column and a mobile phase of 50% methanol/50% water.
• Compound 11 has a retention time of 11.25 minutes and upon radiation produced a new peak with a retention time of 8.58 minutes.
• Authentic benzyl DC-81 has an identical retention time of 8.58 minutes.
• the time course of the deprotection process is shown in figure 5. Complete conversion is achieved by 2 hours of irradiation at 365nm under the conditions employed.
• An MTT assay was used to evaluate the ability of aliquots of the activated analogues, which were removed at time intervals, to inhibit the growth of chronic human histiocytic leukaemia K562 cells in culture. Following treatment of cells with a range of drug doses, cells were transferred to 96-well microtitre plates, 10 4 cells per well, 8 wells per sample. Plates were incubated at 37°C in a humidified atmosphere containing 5% C0 2 .
• the assay is based on the ability of viable cells to reduce a yellow soluble tetrazolium salt 3- ( 4 , 5-dimethylthiazolyl ) -2 , 5- diphenyltetrazolium bromide (MTT) , to an insoluble purple formazan precipitate.
• MTT 5- diphenyltetrazolium bromide
• DMSO 200 ⁇ L
• the optical density was then measured at a wavelength of 550 nm on a Titertek Multiscan ELISA plate reader and expressed as a percentage of the control optical density. For each curve, an IC 50 value was read as the dose required to reduce the final optical density to 50% of the control value.
• the dimer derivative 32 see example 5(b), was found to be slightly cytotoxic before UV irradiation with an IC 50 of 4.5 ⁇ M. Incubation of a solution of compound 32 with cells following 2 hours irradiation reduced the IC 50 to 1.25 ⁇ M (figure 9). This was further reduced to 0.85 ⁇ M following 5 hours irradiation.
• the parent PBD dimer DSB-120 gave an IC 50 of 0.55 ⁇ M in the same cell line, see Figure 9.
• Single viable cells were seeded in growth medium (160 ⁇ L) in 96- well microtitre plates and allowed to attach overnight.
• the test compounds were then dissolved in DMSO (to give 20 mM drug concentrations) immediately prior to adding the cells in quadruplicate wells.
• the final drug concentrations in the wells ranged from lOO ⁇ M to 2.5nM as follows: 100, 25, 10, 2.5, 1 ⁇ M, 250, 100, 25, 10, 2.5 nM (drugs were diluted in growth medium and then 40 ⁇ L added to the existing well volume of 160 ⁇ L to give final concentrations as above) .
• the medium was removed and the remaining cells fixed by exposure to 10% trichloroacetic acid on ice for 30 minutes.
• the wells were then washed 3-4 times with tap water, air dried overnight and treated with 100 ⁇ L of sulphorhodamine B (0.4%) dissolved in 1% acetic acid. Staining was allowed to continue for 10-15 minutes, then the wells were washed 3-4 times with 1% acetic acid, air dried and then added to Tris base (100 ⁇ L of lOmM) . Plates were then shaken and absorbance readings at 540 nM were determined using a plate reader. The IC 50 values were calculated from plots of concentration versus percentage absorbance (compared with 8 untreated wells).
• RF is the resistance factor, which is the cytotoxicity of the compound in the cisplatin resistant cell line divided by the cytotoxicity in the normal cell line.
• the Psec-protected prodrug (52) UP2073 was found to be at least 50 times more toxic than the Ptec control.
• the compound was particularly active against the SKOV3 cell line; this is noteworthy as this cell line is intrinsically resistant to electrophilic cytotoxic agents due to the presence of high levels of glutathione/glutathione transferase.
• the Psec prodrug UP2073 was actually more active in this cell line than the PBD it was based upon UP2025. Without wishing to be bound by theory, it is possible that the prodrug is protected from glutathione and other biological nucleophiles until it is deprotected close to the site of action.
• NCI National Cancer Institute
• NCI National Cancer Institute
• the NCI has available an in vi tro cytotoxicity screen which consists of approximately 60 human tumour cell lines against which compounds are tested at a minimum of five concentrations each differing 10- fold.
• a 48 hour continuous exposure protocol is used, where cell viability or growth is estimated with an SRB protein assay.
• test compound was evaluated against approximately 60 human tumour cell lines.
• the NCI screening procedures were described in detail by Monks and co-workers (Monks, A et al . , Journal of the National Cancer Institute, 1991, 83, 757) . Briefly, cell suspensions were diluted according to the particular cell type and the expected target cell density (5000-40,000 cells per well based on cell growth characteristics), and added by pipette (100 UL) into 96-well microtitre plates. The cells were allowed a preincubation period of 24 hours at 37°C for stabilisation.
• test compounds were evaluated at five 10-fold dilutions (10 ⁇ 4 , 10 "5 , 10' 6 , 10" 7 and 10 "8 ⁇ M) .
• the test compounds were incubated for 48 hours in 5% C0 2 atmosphere and 100% humidity.
• the cells were then assayed using the sulphorhodamine B assay.
• a plate reader was used to read the optical densities and a microcomputer processed the readings into LC 50 values, which is the dosage required to kill half of the cells. IC 50 values, the dosage required to inhibit the growth of half the cells, was also measured.
• Figure 6 & 7 ( ⁇ ) Benzyl DC-81; ( ⁇ ) Compound 11; (•) Compound 11 + UVA 30 mins; (O) Compound 11 + UVA lh; (A) Compound 11 + UVA 2 h.
• Figure 8 ( ⁇ ) Benzyl DC-81; (D) Compound 11; (•) Compound 11 + UVA 30 mins; (O) Compound 11 + UVA lh; (A) Compound 11 + UVA 2 h
• Figure 9 ( ⁇ ) DSB-120; ( ⁇ ) Compound 32; (•) Compound 32 + UVA 30 mins; (O) Compound 32 + UVA lh; (A) Compound 32 + UVA 2h; ( ⁇ ) Compound 32 + UVA 5h

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pyrrole Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (3)

Family

ID=10837953

Family Applications (1)

Country Status (12)

Cited By (103)

Families Citing this family (33)

Citations (1)

Family Cites Families (19)

• 1998
  • 1998-08-27 GB GBGB9818731.3A patent/GB9818731D0/en not_active Ceased
• 1999
  • 1999-08-27 ES ES99941766T patent/ES2205872T3/es not_active Expired - Lifetime
  • 1999-08-27 NZ NZ510492A patent/NZ510492A/en not_active IP Right Cessation
  • 1999-08-27 JP JP2000571053A patent/JP4669611B2/ja not_active Expired - Lifetime
  • 1999-08-27 AT AT99941766T patent/ATE246687T1/de active
  • 1999-08-27 EP EP99941766A patent/EP1109811B1/en not_active Expired - Lifetime
  • 1999-08-27 DK DK99941766T patent/DK1109811T3/da active
  • 1999-08-27 DE DE69910227T patent/DE69910227T2/de not_active Expired - Lifetime
  • 1999-08-27 US US09/763,814 patent/US6562806B1/en not_active Expired - Lifetime
  • 1999-08-27 PT PT99941766T patent/PT1109811E/pt unknown
  • 1999-08-27 WO PCT/GB1999/002837 patent/WO2000012507A2/en active IP Right Grant
  • 1999-08-27 CA CA002341968A patent/CA2341968C/en not_active Expired - Lifetime
• 2003
  • 2003-03-04 US US10/379,049 patent/US20030195196A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events